TP53 and cancer: After the discovery that the tumor suppressor TP53 gene is mutated in more than 50% of all cancers, advances from both basic science and clinical settings led to new strategies through which p53 can be re-activated, mutated p53 degraded, or synthetic lethal mechanisms to eliminate cancer cells [3–7].